Ann Oncol 2015; 25: 611–618 (doi: 10.1093/annonc/mdt556)
In the original manuscript, there was an error in the affiliation of Dr. Curigliano.
The corrected affiliations are as above.
. 2015 Jun 22;26(7):1518. doi: 10.1093/annonc/mdv241
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M V Dieci
1,2,3, C Criscitiello
4, A Goubar
1, G Viale
5,6, P Conte
2,3, V Guarneri
2,3, G Ficarra
7, M C Mathieu
8, S Delaloge
1,9, G Curigliano
4, F Andre
1,9,10
M V Dieci
1INSERM Unit U981, Institut Gustave Roussy, Villejuif, France
2Department of Oncological and Surgical Sciences, University of Padua, Padua
3Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova
Find articles by M V Dieci
C Criscitiello
4Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano
Find articles by C Criscitiello
G Viale
5Department of Pathology, Istituto Europeo di Oncologia, Milano
6Faculty of Medicine, University of Milan, Milano
Find articles by G Viale
P Conte
2Department of Oncological and Surgical Sciences, University of Padua, Padua
3Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova
Find articles by P Conte
V Guarneri
2Department of Oncological and Surgical Sciences, University of Padua, Padua
3Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova
Find articles by V Guarneri
G Ficarra
7Division of Pathology, Modena University Hospital, Modena, Italy
Find articles by G Ficarra
S Delaloge
1INSERM Unit U981, Institut Gustave Roussy, Villejuif, France
9Medical Oncology, Institut Gustave Roussy, Villejuif
Find articles by S Delaloge
G Curigliano
4Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano
Find articles by G Curigliano
F Andre
1INSERM Unit U981, Institut Gustave Roussy, Villejuif, France
9Medical Oncology, Institut Gustave Roussy, Villejuif
10Faculty of Medicine, Paris Sud University, Kremlin-Bicêtre, France
Find articles by F Andre
1INSERM Unit U981, Institut Gustave Roussy, Villejuif, France
2Department of Oncological and Surgical Sciences, University of Padua, Padua
3Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova
4Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano
5Department of Pathology, Istituto Europeo di Oncologia, Milano
6Faculty of Medicine, University of Milan, Milano
7Division of Pathology, Modena University Hospital, Modena, Italy
8Departments of Medical Biology and Pathology
9Medical Oncology, Institut Gustave Roussy, Villejuif
10Faculty of Medicine, Paris Sud University, Kremlin-Bicêtre, France
Issue date 2015 Jul.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PMCID: PMC5266091 PMID: 26109735
This corrects the article "Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study" in volume 25 on page 611.